Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | CCKAR | P32238 | 1/20 | 0.32 |
| ▸ | CCKBR | P32239 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30759380 | 1.00 | SCN9A (0.39) | SCN9AMDM2CTSLCTSBROCK2 | |
| SCHEMBL27041499 | 0.93 | MDM2 (0.38) | SCN9AMDM2CTSLCTSBREN | |
| SCHEMBL30759444 | 0.93 | MDM2 (0.38) | SCN9AMDM2CTSLCTSBREN | |
| SCHEMBL27041496 | 0.93 | MDM2 (0.38) | SCN9AMDM2CTSLCTSBREN | |
| SCHEMBL30759426 | 0.90 | SCN9A (0.34) | SCN9AMDM2CTSLCTSBCCKAR | |
| SCHEMBL27041547 | 0.85 | PTPN1 (0.32) | SCN9AMDM2CTSLCTSBPTPN1 | |
| SCHEMBL27041572 | 0.85 | PTPN1 (0.32) | SCN9AMDM2CTSLCTSBPTPN1 | |
| SCHEMBL30759394 | 0.82 | CTSL (0.46) | SCN9AMDM2CTSLCTSBPTPN1 | |
| SCHEMBL30759472 | 0.76 | SCN9A (0.37) | SCN9AROCK2 | |
| SCHEMBL30759404 | 0.76 | MDM2 (0.42) | SCN9AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | SCN9A 590/4885MDM2 85/4885CTSL 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.